AbbVie
As of the edition of 20 October 2026, AbbVie runs 324 drugs, 153 of them marketed; it is on route A at 49 targets and on route B at 48 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
AbbVie was merged in 2017.
The records place 15 company names in this family.
- ABBVIE: merged in 2017
- Repros Therapeutics Inc.: acquired in 2017; successor Allergan
- Pharmacyclics Switzerland GmbH: acquired in 2018; successor ABBVIE
- Allergan: renamed in 2020
- Allergan Herbert Skin Care Div Allergan Inc: acquired in 2020; successor ABBVIE
- Allergan Pharmaceutical: acquired in 2020; successor ABBVIE
- Allergan Pharmaceuticals International Ltd: acquired in 2020; successor ABBVIE
- Allergan Sales Llc: acquired in 2020; successor ABBVIE
- Soliton: acquired in 2021; successor ABBVIE
- Cerevel Therapeutics, LLC: acquired in 2024; successor ABBVIE
Drugs by status
| Status | Count |
|---|---|
| Marketed | 153 |
| Active | 57 |
| Went quiet | 31 |
| Stopped | 67 |
| Status not established | 16 |
| Total | 324 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Dexamethasone | none listed | 5 |
| Fluorouracil | none listed | 2 |
| Venetoclax | Ends 2032 (patent) | 1 |
| Ritonavir | none listed | 0 |
| Cyclosporine | none listed | 3 |
| Morphine | none listed | 2 |
| Adalimumab | Ends 2028 (orphan exclusivity) | 4 |
| Prednisolone | none listed | 6 |
| Botulinum toxin type a | none listed | 2 |
| Ibrutinib | Ends 2033 (patent) | 2 |
| Sevoflurane | none listed | 12 |
| Leuprolide | Ended 2026 (exclusivity) | 1 |
| Escitalopram | Ended 2026 (exclusivity) | 4 |
| Valproic acid | none listed | 2 |
| Ketorolac | none listed | 6 |
| Progesterone | none listed | 3 |
| Hydrochlorothiazide | none listed | 4 |
| Estradiol | Ends 2032 (patent) | 6 |
| Onabotulinumtoxina | Ended 2026 (orphan exclusivity) | 0 |
| Clarithromycin | none listed | 0 |
| Testosterone | none listed | 4 |
| Ethinyl estradiol | none listed | 5 |
| Triamcinolone acetonide | none listed | 3 |
| Lopinavir | none listed | 0 |
| Levodopa | none listed | 4 |
A route B row is one company at one target. 128 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 49 targets, route B at 48 targets.
All 97 rows on route A or B
In the product97 company-target rows on route A or B; 94 are not shown here, and no score is.
See all 97 targets where AbbVie needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Cancer: 288 trials led
- Immune system: 180 trials led
- Skin and connective tissue: 148 trials led